Insulet Corporation PODD recently received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a new ...

Insulet Corporation PODD recently made its Omnipod 5 Automated Insulin Delivery (“AID”) System commercially available in Australia. Omnipod 5 is available with Dexcom G6 and G7 continuous glucose ...

Insulet Corporation (NASDAQ:PODD) shares are trading higher after the company reported preliminary second-quarter results. The company reported preliminary revenue of $488 million for the second ...

Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

Omnipod 5 has been a major revenue catalyst for Insulet since its release. At the same time, operating expenses associated with Omnipod 5 are higher because of demand exceeding expectations. Higher ...

Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod brand of products, has announced the expansion of its U.S. Pod ...

Insulet Corp. PODD announced that its Omnipod 5 Automated Insulin Delivery (“AID”) System is now compatible with Abbott’s ABT FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the ...